» Articles » PMID: 30448542

Proteoglycan 4 Deficiency Protects Against Glucose Intolerance and Fatty Liver Disease in Diet-induced Obese Mice

Overview
Publisher Elsevier
Date 2018 Nov 19
PMID 30448542
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: Proteoglycan 4 (Prg4) has emerged from human association studies as a possible factor contributing to weight gain, dyslipidemia and insulin resistance. In the current study, we investigated the causal role of Prg4 in controlling lipid and glucose metabolism in mice.

Methods: Prg4 knockout (KO) mice and wild-type (WT) littermates were challenged with an obesogenic high-fat diet (45% of total calories as fat) for 16 weeks. To further stimulate the development of metabolic alterations, 10% fructose water was provided starting from week 13.

Results: Prg4 deficiency only tended to reduce diet-induced body weight gain, but significantly improved glucose handling (AUC: -29%; p < 0.05), which was also reflected by a tendency towards a reduced HOMA-IR score (-49%; p = 0.06 as compared to WT mice). This coincided with lower hepatic expression of glycolysis (Gck: -30%; p < 0.05) and lipogenesis (Acc: -21%; p < 0.05 and Scd1: -38%; p < 0.001) genes, which translated in significantly lower hepatic triglyceride levels (-56%; p < 0.001) in Prg4 KO mice as compared to WT mice. Prg4 KO mice likely had lower glucose utilization by skeletal muscle as compared to WT mice, judged by a significant reduction in the genes Glut4 (-29%; p < 0.01), Pfkm (-21%; p < 0.05) and Hk2 (-39%; p < 0.001). Moreover, Prg4 KO mice showed a favorable white adipose tissue phenotype with lower uptake of triglyceride-derived fatty acids (-46%; p < 0.05) and lower gene expression of inflammatory markers Cd68, Mcp1 and Tnfα (-65%, -81% and -63%, respectively; p < 0.01) than WT mice.

Conclusion: Prg4 KO mice are protected from high-fat diet-induced glucose intolerance and fatty liver disease.

Citing Articles

Plasma proteome variation and its genetic determinants in children and adolescents.

Niu L, Stinson S, Holm L, Lund M, Fonvig C, Cobuccio L Nat Genet. 2025; 57(3):635-646.

PMID: 39972214 PMC: 11906355. DOI: 10.1038/s41588-025-02089-2.


Adipose tissue macrophage heterogeneity in the single-cell genomics era.

Kang H, Lee J Mol Cells. 2024; 47(2):100031.

PMID: 38354858 PMC: 10960114. DOI: 10.1016/j.mocell.2024.100031.


Changes in the Proteome Profile of People Achieving Remission of Type 2 Diabetes after Bariatric Surgery.

Iqbal Z, Fachim H, Gibson J, Baricevic-Jones I, Campbell A, Geary B J Clin Med. 2021; 10(16).

PMID: 34441954 PMC: 8396849. DOI: 10.3390/jcm10163659.


Immunomodulatory Role of the Extracellular Matrix Within the Liver Disease Microenvironment.

McQuitty C, Williams R, Chokshi S, Urbani L Front Immunol. 2020; 11:574276.

PMID: 33262757 PMC: 7686550. DOI: 10.3389/fimmu.2020.574276.


Proteoglycan-4 is correlated with longer survival in HCC patients and enhances sorafenib and regorafenib effectiveness via CD44 in vitro.

Dituri F, Scialpi R, Schmidt T, Frusciante M, Mancarella S, Lupo L Cell Death Dis. 2020; 11(11):984.

PMID: 33199679 PMC: 7669886. DOI: 10.1038/s41419-020-03180-8.